Omeprazole (A2845): Technical Guidance for Gastric Acid Secretion Research

What This Product Solves

Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor formulated to support research into gastric acid secretion mechanisms, antiulcer activity, and models of gastric acid-related disorders. As a chemically defined compound—3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide—Omeprazole enables precise and reproducible study of proton pump inhibition in vitro and in vivo settings (source: product_spec). Its high purity (~98%) and validated physicochemical characteristics are intended to minimize confounding variables in antiulcer activity studies or peptic ulcer disease models. Researchers turn to this reagent when standardization, batch-to-batch consistency, and robust physicochemical data are critical for endpoint reliability.

Omeprazole should not be used in diagnostic or therapeutic workflows. It is explicitly restricted to research contexts where control over assay conditions and compound handling is feasible and documented.

Protocol Parameters

• assay: H+,K+-ATPase inhibition assay | value_with_unit: IC50 = 5.8 μM | applicability: Selectivity benchmarking and initial dose finding for proton pump inhibition studies | rationale: Provides a quantitative reference for optimizing concentration in enzyme-based and cell-based assays | source_type: product_spec (product_spec)
• assay: Histamine-induced gastric acid formation | value_with_unit: IC50 = 0.16 μM | applicability: Evaluating efficacy in gastric acid secretion models | rationale: Supports protocol design for studies on histamine-stimulated acid production, commonly used in antiulcer agent screening | source_type: product_spec (product_spec)
• assay: Compound solubility (DMSO) | value_with_unit: ≥17.27 mg/mL | applicability: Preparation of concentrated stock solutions for in vitro and in vivo dosing | rationale: Enables accurate stock preparation without precipitation, critical for assay reproducibility | source_type: product_spec (product_spec)
• assay: Storage condition (solid) | value_with_unit: -20°C | applicability: Long-term material preservation | rationale: Reduces risk of degradation and preserves compound integrity; solution forms should only be used short-term | source_type: product_spec (product_spec)
• assay: Vehicle compatibility | value_with_unit: Insoluble in water/ethanol | applicability: Solubilization planning for cell and animal studies | rationale: Avoids failed dissolutions and inconsistent dosing | source_type: product_spec (product_spec)

Workflow Setup and QC Checklist

• Compound Reception: Upon delivery (typically on blue ice for stability), confirm intact packaging, absence of moisture ingress, and proper labeling. Immediately transfer Omeprazole to a -20°C freezer as a solid to ensure long-term stability (product_spec).
• Stock Solution Preparation: Dissolve Omeprazole in 100% DMSO to a concentration not exceeding its solubility threshold (≥17.27 mg/mL). Use low-retention tubes to minimize material loss and vortex thoroughly to ensure homogeneity. Avoid water and ethanol due to insolubility.
• Aliquoting: Prepare working aliquots to minimize freeze-thaw cycles. Use single-use aliquots where possible to avoid repeated thermal exposure, which can degrade compound quality.
• Short-Term Solution Storage: Use prepared solutions immediately or store at -20°C for short periods only; avoid long-term storage in solution, as per product guidance.
• QC Verification: Verify solution clarity and absence of precipitate before use. If precipitate or cloudiness occurs, re-dissolve by gentle heating (if compatible with assay) or discard aliquot and prepare a fresh one.
• Assay Setup: For H+,K+-ATPase inhibition or gastric acid secretion research, select concentrations informed by provided IC50 values and titrate as needed for your specific model (internal_article).

Common Failure Modes and Fixes

• Incomplete Solubilization: If Omeprazole does not fully dissolve in DMSO, verify solvent purity and temperature. Use gentle vortexing or brief sonication. Do not attempt to dissolve in water or ethanol, as this will not yield a usable solution (source: product_spec).
• Precipitation in Aqueous Media: When diluting DMSO stock into buffer or media, add slowly with continuous mixing. Keep final DMSO concentration within assay-tolerated limits. If precipitation occurs, reduce stock concentration or increase DMSO carryover within permissible levels.
• Compound Degradation: If loss of activity is observed, check for repeated freeze-thaw cycles or prolonged solution storage. Always aliquot and avoid storing working solutions for extended periods (source: product_spec).
• Batch Variability: Confirm lot number and purity on CoA. For critical studies, validate compound identity by mass spectrometry or NMR as a secondary check.

Scope and Limitations

• This product is validated for in vitro and in vivo research on gastric acid secretion, proton pump inhibition, and antiulcer activity (source: product_spec).
• It should not be used in diagnostic or medical workflows. No claims are made for efficacy or safety outside controlled laboratory investigations.
• Effectiveness in gastric acid-related disorder models is contingent on assay design and adherence to physicochemical guidelines. There is no direct evidence for use in unrelated biological systems; researchers should consult internal articles such as scenario-based guidance for workflow-specific troubleshooting.
• Limitations include solvent compatibility, solution stability, and the need for precise dosing to avoid off-target effects.

Conclusion

Omeprazole (A2845) offers a rigorously characterized, reproducible tool for gastric acid secretion research and antiulcer activity studies. By adhering closely to storage, solubilization, and dosing parameters, researchers can minimize variability and maximize data reliability. For additional scenario-driven troubleshooting or protocol refinement, reference is made to both internal guidance articles and the APExBIO product page for the latest procedural recommendations.